RMTG Subsidiary CELLGENIC Introduces Peptide Pen Product Line at Cancún Global Summit

Core Insights - Regenerative Medical Technologies Group, Inc. has launched its CELLGENIC Peptide Pen product line, enhancing its position in the regenerative medicine market [1] - The introduction of this product line aims to simplify and modernize peptide therapy, aligning with trends in longevity medicine [1] - The new product line is expected to generate additional revenue through the company's established physician distribution network across over 30 countries [1] Company Overview - Regenerative Medical Technologies Group, Inc. is recognized as a global leader in regenerative medicine solutions [1] - The company is actively expanding its product offerings to meet the growing demand for innovative medical therapies [1] Market Impact - The launch of the CELLGENIC Peptide Pen is positioned to create new revenue streams, indicating a strategic move to capitalize on the expanding market for peptide therapies [1] - The product line's introduction during the ISSCA Global Summit highlights the company's commitment to innovation and leadership in the field [1]